Company profile: Third Harmonic Bio
1.1 - Company Overview
Company description
- Provider of a clinical-stage, first-in-class, highly selective oral small molecule KIT inhibitor for mast cell-mediated inflammatory diseases; THB335 is being developed for chronic spontaneous urticaria, severe asthma, and other related conditions.
Products and services
- THB335 – Chronic Spontaneous Urticaria: First-in-class oral small-molecule KIT inhibitor developed for chronic spontaneous urticaria in mast cell-mediated inflammatory disease settings
- THB335 – Severe Asthma: Clinical-stage oral small-molecule KIT inhibitor being developed for severe asthma and related mast cell-mediated inflammatory conditions
- THB335 – Additional Mast Cell-Mediated Diseases: Highly selective oral small-molecule KIT inhibitor advanced for other mast cell-mediated inflammatory diseases beyond urticaria and severe asthma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Third Harmonic Bio
Amira Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule pharmaceutical research focused on the discovery and early development of new drugs to treat inflammatory disease, leveraging unparalleled insights into bioactive lipid pathways and complex signaling processes controlling conditions including asthma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amira Pharmaceuticals company profile →
Orca Bio
HQ: United States
Website
- Description: Provider of clinical-stage, high-precision cell therapies dedicated to delivering curative medicine. Products include Orca-T, which replaces a patient's diseased blood and immune system with a healthy one while reducing the risk of GvHD and other side effects, and Orca-Q, for patients with haploidentical donors, designed to offer therapeutic benefits while minimizing the risk of acute and chronic GvHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orca Bio company profile →
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
Acelyrin
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, identifying, acquiring, and accelerating development and commercialization of candidates including Izokibep (IL-17A inhibitor for psoriatic arthritis and hidradenitis suppurativa), Lonigutamab (subcutaneous anti-IGF-1R for thyroid eye disease), and SLRN-517 (fully human monoclonal targeting c-KIT for chronic urticaria and other mast cell-driven diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acelyrin company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Third Harmonic Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Third Harmonic Bio
2.2 - Growth funds investing in similar companies to Third Harmonic Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Third Harmonic Bio
4.2 - Public trading comparable groups for Third Harmonic Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →